Comera Life Sciences To Become Publicly Traded via Business Combination With OTR Acquisition Corp.; Combined Co. To Have Implied Equity Vale $258.4M

• Comera Life Sciences is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience
• This transaction is expected to enable further investment in a compassionate new era in medicine by applying a deep knowledge of formulation science and technology to transform essential biologic medicines from intravenous to subcutaneous forms and thereby give patients greater flexibility in their care
• Combined company to have an implied initial equity value of approximately $258.4 million translating into an enterprise value of approximately $151.3 million, with the proposed business combination expected to provide approximately $107 million in gross proceeds, assuming no redemptions by stockholders of OTR Acquisition Corp.
• All existing Comera investors are rolling 100% of their equity into the pro forma company
• The proposed business combination is expected to be completed in the second quarter of 2022
• Investor call with Comera and OTR scheduled for Friday, Feb. 4 at 8:30 a.m. EST

Comera Life Sciences, Inc. ("Comera" or the "Company"), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, and OTR Acquisition Corp. (NASDAQ:OTRAU, OTRA and OTRAW))))) (collectively referred herein as "OTR"), a publicly traded special purpose acquisition company (SPAC), today announced they have entered into a business combination agreement. The transaction is expected to provide Comera with access to the public equity markets and thereby position Comera to accelerate the development and advancement of its internal portfolio of subcutaneous (SQ) therapeutics incorporating the Company's innovative proprietary SQore™ formulation platform.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220130005060/en/

OTR is a $107 million SPAC led by veteran investor and entrepreneur Nicholas J. Singer, who serves as Chairman and Chief Executive Officer. The team is comprised of growth-oriented executives with a long track record of value creation across industries, including life sciences, bringing over 100 years of combined investing and operating experience to this business combination.

Following the closing of the transaction, the combined company will continue to operate under the Comera management team led by Jeff Hackman, Chief Executive Officer; Neal Muni, M.D., Chief Operating Officer; Kevin Kavanaugh, Chief Financial Officer; and Robert Mahoney, Ph.D., Chief Scientific Officer. Jim Sherblom will continue to serve as Executive Chairman of the Comera Board of Directors.